GOBBI, GIULIA
GOBBI, GIULIA
DIPARTIMENTO DI FARMACIA E BIOTECNOLOGIE
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling
2023 Gobbi G.; Grieco A.; Torricelli F.; Sauta E.; Santandrea G.; Zanetti E.; Fantini V.; Reggiani F.; Strocchi S.; Paci M.; Vohra M.; Saladi S.V.; Ambrosetti D.C.; Ciarrocchi A.; Sancisi V.
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma
2021 Reggiani F.; Sauta E.; Torricelli F.; Zanetti E.; Tagliavini E.; Santandrea G.; Gobbi G.; Damia G.; Bellazzi R.; Ambrosetti D.; Ciarrocchi A.; Sancisi V.
Csnk1a1, kdm2a, and ltb4r2 are new druggable vulnerabilities in lung cancer
2021 Sauta E.; Reggiani F.; Torricelli F.; Zanetti E.; Tagliavini E.; Santandrea G.; Gobbi G.; Strocchi S.; Paci M.; Damia G.; Bellazzi R.; Ambrosetti D.; Ciarrocchi A.; Sancisi V.
Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy
2020 Reggiani F.; Gobbi G.; Ciarrocchi A.; Ambrosetti D.C.; Sancisi V.
The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells
2019 Gobbi G.; Donati B.; Do Valle I.F.; Reggiani F.; Torricelli F.; Remondini D.; Castellani G.; Ambrosetti D.C.; Ciarrocchi A.; Sancisi V.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling | Gobbi G.; Grieco A.; Torricelli F.; Sauta E.; Santandrea G.; Zanetti E.; Fantini V.; Reggiani F.;... Strocchi S.; Paci M.; Vohra M.; Saladi S.V.; Ambrosetti D.C.; Ciarrocchi A.; Sancisi V. | 2023-01-01 | CELL DEATH & DISEASE | - | 1.01 Articolo in rivista | s41419-023-06277-y.pdf; 41419_2023_6277_MOESM1_ESM.pdf; 41419_2023_6277_MOESM2_ESM.xlsx; 41419_2023_6277_MOESM3_ESM.xlsx; 41419_2023_6277_MOESM4_ESM.pdf |
| An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma | Reggiani F.; Sauta E.; Torricelli F.; Zanetti E.; Tagliavini E.; Santandrea G.; Gobbi G.; Damia G....; Bellazzi R.; Ambrosetti D.; Ciarrocchi A.; Sancisi V. | 2021-01-01 | MOLECULAR CANCER | - | 1.01 Articolo in rivista | s12943-021-01357-z.pdf |
| Csnk1a1, kdm2a, and ltb4r2 are new druggable vulnerabilities in lung cancer | Sauta E.; Reggiani F.; Torricelli F.; Zanetti E.; Tagliavini E.; Santandrea G.; Gobbi G.; Strocch...i S.; Paci M.; Damia G.; Bellazzi R.; Ambrosetti D.; Ciarrocchi A.; Sancisi V. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-13-03477.pdf |
| Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy | Reggiani F.; Gobbi G.; Ciarrocchi A.; Ambrosetti D.C.; Sancisi V. | 2020-01-01 | BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | - | 1.01 Articolo in rivista | Review YAP and TAZ_REV2_clean no numeri.docx |
| The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells | Gobbi G.; Donati B.; Do Valle I.F.; Reggiani F.; Torricelli F.; Remondini D.; Castellani G.; Ambr...osetti D.C.; Ciarrocchi A.; Sancisi V. | 2019-01-01 | ONCOGENE | - | 1.01 Articolo in rivista | - |